{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:12:48Z","timestamp":1786990368690,"version":"build-2736575974"},"reference-count":17,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Tetraphase Pharmaceuticals, Inc."},{"name":"Biomedical Advanced Research and Development Authority, Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services","award":["HHSO100201200002C"],"award-info":[{"award-number":["HHSO100201200002C"]}]}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1016\/j.ijantimicag.2018.01.001","type":"journal-article","created":{"date-parts":[[2018,1,8]],"date-time":"2018-01-08T13:06:14Z","timestamp":1515416774000},"page":"727-732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic\/pharmacodynamic analysis"],"prefix":"10.1016","volume":"51","author":[{"given":"Abrar K.","family":"Thabit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marguerite L.","family":"Monogue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph V.","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David P.","family":"Nicolau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2018.01.001_bib0010","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1517\/14656566.2015.993381","article-title":"Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials","volume":"16","author":"Thabit","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ijantimicag.2018.01.001_bib0015","doi-asserted-by":"crossref","first-page":"5548","DOI":"10.1128\/AAC.01288-13","article-title":"Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens","volume":"57","author":"Sutcliffe","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.001_bib0020","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1128\/AAC.01614-13","article-title":"Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections","volume":"58","author":"Solomkin","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.001_bib0025","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating Gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ijantimicag.2018.01.001_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.01.001_bib0035","doi-asserted-by":"crossref","first-page":"5072","DOI":"10.1128\/AAC.00240-16","article-title":"Eravacycline pharmacokinetics and challenges in defining humanized exposure in vivo","volume":"60","author":"Thabit","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.001_bib0040","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.1128\/AAC.00366-16","article-title":"Antibacterial efficacy of eravacycline in vivo against Gram-positive and Gram-negative organisms","volume":"60","author":"Monogue","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.001_bib0045","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1086\/510079","article-title":"Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore","volume":"44","author":"Ambrose","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.01.001_bib0050","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jac\/dkl224","article-title":"Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines","volume":"58","author":"Agwuh","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.001_bib0055","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00250-17","article-title":"In vivo pharmacodynamic target assessment of eravacycline against Escherichia coli in a murine thigh infection model","volume":"61","author":"Zhao","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.001_bib0060","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1128\/AAC.01824-12","article-title":"Tigecycline displays in vivo bactericidal activity against extended-spectrum-\u03b2-lactamase-producing Enterobacteriaceae after 72-hour exposure period","volume":"57","author":"Tessier","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.001_bib0065","series-title":"M07-A10: methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","author":"Clinical and Laboratory Standards Institute","year":"2015"},{"key":"10.1016\/j.ijantimicag.2018.01.001_bib0070","series-title":"M100-S26: performance standards for antimicrobial susceptibility testing: twenty-sixth informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2016"},{"key":"10.1016\/j.ijantimicag.2018.01.001_bib0075","series-title":"Efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: defining eravacycline fAUC\/MIC magnitudes for Enterobacteriaceae using humanized exposures in an in vivo model","author":"Thabit","year":"2016"},{"key":"10.1016\/j.ijantimicag.2018.01.001_bib0080","series-title":"Efficacy of fluorocycline TP-434 in the neutropenic thigh infection model is predicted by AUC\/MIC, abstract F1-2164","author":"Weiss","year":"2010"},{"key":"10.1016\/j.ijantimicag.2018.01.001_bib0085","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1128\/AAC.02036-13","article-title":"Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women","volume":"58","author":"Connors","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.01.001_bib0090","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1128\/AAC.04809-14","article-title":"Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City","volume":"59","author":"Abdallah","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918300013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918300013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,8,24]],"date-time":"2018-08-24T16:55:47Z","timestamp":1535129747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918300013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S0924857918300013"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.01.001","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of in vivo efficacy of eravacycline against Enterobacteriaceae exhibiting various resistance mechanisms: a dose-ranging study and pharmacokinetic\/pharmacodynamic analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.01.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}